Life Sciences Archive » August, 2024

Life Sciences - August, 2024

289 articles

• McKesson, Others To Pay Benefit Plans $300M In Opioid Deal
• Calif. Legislature OKs Ban On 6 Food Dyes In Public Schools
• Doctor In Matthew Perry's Death Makes 1st Court Appearance
• Wheeling & Appealing: The Latest Must-Know Appellate Action
• Align Tech Cuts $27.5M Antitrust Deal With 1.45M Consumers
• Nebraska Expected To Vote On Medical Marijuana Legalization
• Period Tracker App Users Seek Class Cert. In Data-Selling Suit
• Bayer Antitrust Case Hinged On Evolving Market Definition
• Philips Accuses SoClean Of Discovery Delay In CPAP Recall
• IP Hot Topic: The Intersection Of Trademark And Antitrust Law
• Being An Opera Singer Made Me A Better Lawyer
• Cancer Detection Co. Valued At $375M In SPAC Merger
• Fall IPO Pickup Could Be A Prelude For 2025 Recovery
• Pa. Justices To Examine Axing Of 'Red Book' Drug Pricing
• Jury Clears Ore. Hospital That Implanted FDA-Flagged Mesh
• Lannett Says Areva Reneged On Cancer-Drug Deal After Ch. 11
• Comer Tells PBMs To Correct Record On Role In Drug Pricing
• Seattle Biotech Can't Immediately Force Out LA Times Owner
• Pacira To Appeal Generic's Win In Pain Drug Patent Fight
• Nektar Can't Get Docs It Says Show Lilly As 'Thieves, Liars'
• Convicted Drexel Prof Says Records Would've Swayed Jury
• What Drug Cos. Must Know About NY Price Transparency Law
• Jazz Hits Teva With Patent Suit Over Narcolepsy Drug
• How Law Firms Can Avoid 'Collaboration Drag'
• Merck Must Face Class Claims In Vaccine Antitrust Suit
• CyDex Says Bexson Breached Deal By Misusing Pharma IP
• J&J Spinoff Beats Suit Over Tylenol 'Rapid Release' Labels
• Lipitor Buyers Seek Final OK For $35M Deal In Antitrust Fight
• Walgreens Brass Hid Pharmacy Division Woes, Suit Says
• Jazz, Hikma Must Face Bulk Of Xyrem Antitrust Suit
• Calif. Couples Drop FujiFilm Suit Over Destroyed Embryos
• Del. Justices OK Mid-Case Appeal In Zantac Class Suit
• High Court Told Tyvaso Row Petition Based On 'False' Premise
• What BIPA Reform Law Means For Biometrics Litigation
• Regeneron Sues Sandoz Over Dozens Of Eye Drug Patents
• Litigation Funding Disclosure Key To Open, Impartial Process
• Biotech Biz Hid Risks Of Gene-Editing Trial, Investor Claims
• Cherokee Nation's Opioid Suit Sent Back To State Court
• USPTO Sued For Rejecting Blood Pressure Drug Patent
• NY Pension Funds Join Illumina Deal Suit Pile-On In Del.
• Fed. Circ. Won't Speed Up Apple Watch Ban Appeal
• Connecticut Litigation To Watch In The 2nd Half Of 2024
• The Licensure Landscape For Psychedelics Manufacturers
• Sheppard Mullin Adds Another McDermott Healthcare Pro
• Vt. High Court Affirms Denial Of Benefits To Marijuana Patient
• What NFL Draft Picks Have In Common With Lateral Law Hires
• Freshfields Steers UCB's $680M Sale Of Chinese Portfolio
• Rival Can't Avoid Drugmaker's False Ad Claim Over Pain Med
• Biotech Investor Sues In Chancery Over Alleged IP Diversions
• Hikma Urges Full Fed. Circ. To End Vascepa Skinny-Label Suit
• Ex-Ingersoll Rand Exec Could Be Stuck With Noncompete
• Masimo, Apple Fight Over Jury Hearing Trade Secrets Claims
• Shareholder Attys Get $11M For Taro Price-Fixing Deal
• FTC Mulls Proposal To Alter Puerto Rican Pharmacy Deal
• Replacing The Stigma Of Menopause With Law Firm Support
• McKesson Inks $2.49B Deal For Cancer-Focused Biz
• NY Can't Sue Groups Over Abortion 'Reversal' Ads, For Now
• Abbott Judge Suggests $54M Judgment In Test Strip TM Case
• Biotech Co. In Wrongful Death Suit Over Destroyed Embryo
• Matthew Perry Death Suit Could Blow Past Calif. Damage Cap
• McKinsey Opioid Suits Sent Back To NY, Illinois State Courts
• 9th Circ. Reverses 'Patent Misuse' Ruling Against CR Bard
• Ex-Exec Can't Reverse Medtronic Insider Trading Conviction
• The Biggest Product Liability Cases Of 2024: A Midyear Report
• Drugmakers' 'Subjective Beliefs' Obscured In Antitrust Case
• Albertsons-Kroger Deal Tests FTC's Stepped-Up Merger Policy
• Class Actions At The Circuit Courts: August Lessons
• Leveraging Policy Changes To Achieve AI Patent Eligibility
• Covington-Led Getinge Pays $477M For Organ Transplant Biz
• Planning Law Firm Content Calendars: What, When, Where
• Delaware Lets Ventis Move Pacira's False Ad Suit To Calif.
• Firms Seek $20M Fee After $58M Deal In Shire Antitrust Suit
• PBMs Can't Yet Duck Municipalities' Claims In Opioid MDL
• Texas Appeals Knocks $1M Hernia Mesh Fee Ask Down To $135K
• 2 Biotech Firms File Plans To Go Public As IPO Pipeline Grows
• Mich. Panel Upholds Block Of 24-Hour Abortion Waiting Period
• Zantac Cases Must Remain In State Court, Conn. Judge Rules
• Texas Tells High Court It's Not Idaho '2.0' In HHS Abortion Row
• Ex-MiMedx Sales Rep Says Fraud Schemes Pushed Her Out
• USPTO Tells High Court To Skip Double-Patenting Fight
• Ga. Mineral Co., Insurer Strike Deal In Talc Coverage Suit
• Deals Rumor Mill: Saudi Fund, Disney-Reliance, Repligen
• Playing Golf Makes Me A Better Lawyer
• Fed. Circ. Won't Rethink IP Safe Harbor Case
• Spine Implant Caused Patient's TB, Suit Says
• Cannabinoid Co. Sacked Exec For Flagging Fraud, Suit Says
• Hedge Fund Priest Sues SEC Over Proposed Industry Ban
• 9th Circ. Doubts Idaho Trans Health Ban Doesn't Discriminate
• Judge Rules Lack Of Expert Dooms Families' Tylenol MDL
• Law Firms Should Move From Reactive To Proactive Marketing
• Calif. AG Secures Rite Aid Deal Ensuring Pharmacy Access
• Mesh Was Implanted After Serious FDA Alert, Jury Hears
• Ala. AG Can't Prosecute Aiding Abortion Travel, DOJ Says
• SF Police Can't Sue Navy Over Toxic Shipyard, 9th Circ. Says
• Advanced Bionics Sues Med-El At ITC Over Implant Patents
• Lender's $13M Atty Fee Reserve Bid In Eiger Ch. 11 Plan Nixed
• Fed Circ. Finds No Fault In Denial Of Flu Vaccine Claim
• Insider Trading Won't Impact Pilot's Tax Sentencing Guidelines
• Vax Patent Battles Heat Up As Attention On Pandemic Wanes
• Ex-Client Opposes Amicus In McCarter & English Fee Fight
• FTC Endorses Push For Broader Access To Biosimilar Drugs
• Pathology Trade Group 2nd To Sue FDA Over Lab-Test Rule
• The Regulatory Headwinds Facing Lab-Developed Tests
• 3 High Court Rulings May Shape Health Org. Litigation Tactics
• A New Way Forward For COVID Vaccine Lawsuit Immunity
• A Deep Dive Into Law360 Pulse's 2024 Women In Law Report
• These Firms Have The Most Women In Equity Partnerships
• The Big Issues A BigLaw Associates' Union Could Address
• J&J Boosting Cardio Portfolio With Up To $1.7B V-Wave Buy
• TPG Dumped Opioid Co. On 'Unsuspecting' Endo, Suit Says
• Biogen Paid To Help Curb Generic Tecfidera Sales, Says Suit
• NuVasive Beats Fraudulent Inducement Claim At Trial
• 9th Circ. Told Psilocybin Petition Is Backed By Precedent
• Jadex Sells Temperature-Controlled Packaging Biz For $137M
• Second Pharmacist To Avoid Meningitis Murder Trial
• Pennsylvania Litigation Highlights Of 2024: A Midyear Report
• It's Time For A BigLaw Associates' Union
• Israeli Co. Sues NC Packaging Firm For Severing $25M Deal
• Biotech Consultant Sues Ex-Partner To Force $2.5M Share Buy
• Fed. Circ. Quells Fears Over Double-Patenting Overreach
• Humana To Pay $90M To End 8-Year Medicare Drug FCA Battle
• Drexel Accounting Prof Convicted Of Evading Tax On $3.3M
• Baltimore Inks $152.5M Opioid Deal With Cardinal Health
• Birth Control Cos. Say Conn. Injury Suit Must Be Tossed
• How Justices Upended The Administrative Procedure Act
• States Get Teva Generic Price-Fix Case On Docket As 1st Trial
• Walgreens Didn't Disclose PFAS In Bandages, Shopper Says
• Parsing FY 2024 DOJ Criminal Healthcare Fraud Enforcement
• Apple Needs To Wait Its Turn In ITC, Masimo Tells Fed. Circ.
• Ex-CEO Wants Verdict In COVID Test Kit Fraud Case Tossed
• Avantor Sells Clinical Services Biz To PE Shop In $650M Deal
• Psilocybin Right-To-Try Petition To Get 9th Circ. Hearing
• Taxation With Representation: Cleary, Kirkland, Skadden
• NC Litigation Highlights Of 2024: A Midyear Report
• New Jersey Litigation Highlights Of 2024: A Midyear Report
• Talc Jury Delivers $63M Verdict Against J&J, Beauty Care Co.
• NIH Accused Of Wrongly Eliminating Cos. From $50B IT Deal
• Matthew Perry's Assistant And 2 Drs. Charged In Actor's Death
• LA Times Owner Sued Over Control Of Biotech Nonprofit
• Monsanto Gets 3rd Circ. Win In Roundup Failure-To-Warn Case
• Pharmacy Can't Dodge Novo Nordisk's Diabetes Drug Suit
• CMS Posts Final Costs For 1st Set Of Drugs After Negotiations
• Price-Fixing Claims Against Par Pharma Tossed After Ch. 11
• NC Small Biz Challenges VA Bid Process For Prostate Drug
• Pharma Co. TM Dispute Doesn't Belong In Florida, Judge Says
• Okla. Says 10th Circ. PBM Ruling Defies High Court Precedent
• Paul Hastings Adds M&A, Shareholder Activism Lawyer
• Costco Wants PFAS Kirkland Brand Baby Wipes Suit Tossed
• J&J Vision Unit Sues Ex-Marketing Exec Over Move To Rival
• NC Judge OKs $15.2M Deal For Medical Device Investors
• Grassley Asks HHS For Clarity On Cannabis Position
• Novartis' $45B Biz Can Survive If Generic Debuts, Judge Says
• AstraZeneca Freed From $107.5M Verdict In Pfizer Patent Case
• HHS Calls For More Research, Planning To Combat Heat Risks
• Samsung Biotech Unit Hit With Patent Suit Over Bone Drugs
• How Cos. With Chinese Suppliers Should Prep For Biotech Bill
• Calbiotech Beats Ex-Worker's 401(k) Retaliation Suit
• Suit Claims Giant Uses Banned, Toxic Oil In Orange Soda
• Zantac Judge Won't Step Aside Over Wife's Reed Smith Role
• Mirror, Mirror On The Wall, Is My Counterclaim Bound To Fall?
• Can Chapter 15 Bankruptcy Help Cannabis Businesses?
• SEC Drops Insider Trading Suit Against Ex-Mylan Exec
• Entresto Release Delayed As Novartis Goes To Fed. Circ.
• Mother Can't Revive Suit Against GE For Child's Brain Damage
• Spinal Implant Patents Verdict Must Stand, Pa. Judge Says
• NY, NJ And Conn. Score $4.5M Penalty Over Enzo Data Breach
• Janssen Wants New FCA Trial As Relators Seek $1.85B Win
• Fed. Circ. Restores J&J, Allergan's Viberzi IP After Del. Loss
• Former Sprinter Eyes Plea Deal In 2020 Olympics Doping Case
• DC Circ. Backs EPA's Ethylene Oxide Cancer Risk Value
• FTC Makes 2nd Request In Review Of Medical Device Co. Deal
• FTC's Drug Middlemen Probe Highlights Ongoing Scrutiny
• 'Clever' Scheme Is Concealing Talc Litigation Funding, J&J Says
• Ex-McCarter & English Client Wants To Undo Malpractice Loss
• Conn. Trial Attys Back McCarter's Bid For Punitive Award
• Playing Dungeons & Dragons Makes Me A Better Lawyer
• 3 Firms Drive $3.8B Carlyle-Baxter Kidney Care Deal
• Accused Accounting Prof Is No Tax Expert, NJ Jury Told
• States Want Teva Generic Price Fixing Case Tried 1st
• Glass Tempering Co. Loses Early Exit Bid In NC Patent Fight
• Paragard IUD Makers Gearing Up For Defect Dismissal Bid
• States Oppose Shkreli High Court Bid For $64M Disgorgement
• Del. Dispatch: Director Caremark Claims Need Extreme Facts
• Parsing NJ Court's Rationale For Denying Lipitor Class Cert.
• Pacira Patent On Surgery Pain Drug Voided In Win For Generic
• King & Spalding Adds Freshfields M&A Ace In Silicon Valley
• Del. Judge Says Vaccine IP Claim Actually Mandates Vaccine
• The Biggest Georgia Rulings Of 2024 So Far
• Catching Up With Delaware's Chancery Court
• 3 Firms Rep As Crown Buys Revance In $924M Deal
• Takeda Should Face Certified Antitrust Classes, Judge Says
• Delaware Jury Says Fecal Treatment Patents Are Worth $25M
• Valeant's Legal Gripe A Total 'Nothingburger,' Justices Told
• Medicare Drug Price Suit Nixed Over 'Forum Shopping' In Ohio
• Biotech Firms Mull Acquisition Offers Amid Shaky IPO Climate
• FDA Rejects Latest Effort To Treat PTSD With MDMA
• Biopharm Co. Alector Sued In Del. For Docs On Director Pay
• Novartis Wants DC Judge To Quickly Block Entresto Generic
• Pharmacy Escapes Recklessness Claim In Septic Shock Suit
• Vidal's Sanctions Make It Clear: Don't Mess With The PTAB
• Gilead Drug Ruling Creates Corporate Governance Dilemma
• Wash. AG Says Kroger Refusing To Delay Merger For Ruling
• 3 Leadership Practices For A More Supportive Firm Culture
• Merck To Buy Autoimmune Treatment Drug For Up To $1.3B
• UK Litigation Roundup: Here's What You Missed In London
• Mass. Atty, 2 Others Settle SEC Insider Trading Claims
• Pot Cos. Get Creative To Boost Brands Despite Feds' TM Ban
• Apple Wins Bid For 2 Trials In IP Dispute With Masimo
• Cancer Research Org. Is Right To Avoid Corporate Influence
• Cannabis Biz Real Estate Loan Considerations For Lenders
• Cooley Hit With Fla. Malpractice Suit Over Financial Docs
• Wilson Sonsini, A&O Shearman Guide $688M Biotech Merger
• Deals Rumor Mill: Roche, Thoma Bravo, Klarna
• Rising Star: Williams & Connolly's Elise Baumgarten
• E-Discovery Quarterly: Rulings On Hyperlinked Documents
• Exec Unlikely To Get New Trial In SEC's 'Shadow Trading' Suit
• Biotech Firm Can't Pause SEC Action During Appeal
• Abbott Brass Trim But Can't Nix Investors' Formula Recall Suit
• Judge's Pharma Comments Could Decide Ineligibility Appeal
• Advocates Tell 9th Circ. To Revive Invisalign Monopoly Suit
• Teva Finds Some Big-Pharma Friends In Inhaler Patent Fight
• NC Biz Court Bulletin: The Battles Making Summer Sizzle
• Amgen Waged Lawfare To Overcharge For Drug, Suit Claims
• Ex-Pharma Exec Gets 20 Months In SEC Contempt Case
• Loper Bright Limits Federal Agencies' Ability To Alter Course
• Law Firms Fight J&J Bid To Revive Talc Subpoenas
• 3 Firms Steer $405M G1-Pharmacosmos Pharma Deal
• 2 FDA Pros Join McGuireWoods From Reed Smith, DOJ
• Jury Deadlocks In Third Illinois Zantac Cancer Trial
• Rising Star: King & Spalding's Julia Zousmer
• Pennsylvania Legislation Passed In 2024: A Midyear Report
• AstraZeneca Can't Duck $107.5M Patent Loss To Pfizer Unit
• Baby Sock Co. Can't Beat Investor Suit, But SPAC Brass Can
• Fed. Circ. Told Edwards Filed Safe Harbor Suit With Bad Intent
• Tech Giants' Fight To Ax Fintiv Rule Returns To Fed. Circ.
• Denver Food Co. Fired VP For Younger Male, Suit Claims
• Life Sciences Credit Firm Symbiotic Launches With $600M
• FDA Posts Two Policy Memos On E-Cig Applications
• A Primer On EU's Updated Human Substance Regulations
• Pharma Co. Founder Beats Suit Over Short-Swing Trading
• Dem Lawmakers Back FTC's Kroger-Albertsons Challenge
• Ex-Pfizer Worker Who Traded On Paxlovid Secrets Gets 9 Mos.
• Penn Says BioNTech Owes Royalties For COVID-19 Vax
• Teaching Scuba Diving Makes Me A Better Lawyer
• Rising Star: White & Case's Adam Acosta
• The Road Ahead For Regulation Of Digital Twins In Healthcare
• Inari Agriculture Can't Sink Patent Case Over Corn Seed
• Indivior Accused Of Overstating Prospects Of 3 Opioid Drugs
• Chinese Drug Co. Says Sanctions In Valsartan MDL Too Harsh
• J&J, Generics Spar In Remand On Schizophrenia Drug Patent
• GSK Wins Second Ill. Trial On Zantac Cancer Claims
• Lawyers Can Take Action To Honor The Voting Rights Act
• Spectrum, Assertio Hit With Double-Derivative Suit In Del.
• Fla. Man Gets 44 Months For $5M MilliporeSigma Export Scam
• Centessa Beats Shareholder Suit Over Kidney Drug
• Catching Up With Delaware's Chancery Court
• CooperSurgical Says Lab Hid Flawed IVF Product Tests
• Freshfields, Wachtell Guide $925M CVC, Mallinckrodt Deal
• Rising Star: Ropes & Gray's Tara Fisher
• 3rd Circ. Ruling Shows Benefits Of IP Licenses In Bankruptcy
• Unclear Intellectual Property Laws Are Stifling US Innovation
• Health Tech Co. Beats Investor Data Platform Fraud Claim
• Ex-Exec Can't Escape Drug Co.'s Trade Secret Suit
• Wheeling & Appealing: The Latest Must-Know Appellate Action
• US Cannabis Policy Thwarts Research, Health Officials Say
• McKinsey's $78M Opioid Deal With Health Plans Gets OK
• Patients Ink $1M Deal To Settle Pharmacy Data-Breach Claims
• 3rd Circ. Backs Ex-NJ Firefighter's $50M Drug Fraud Sentence
• The Fed. Circ. In June: More Liability For Generic-Drug Makers
• PTAB Told To Punish Mylan For Allegedly Breaking Fintiv Vow
• Four Plaintiffs Tossed From Merck Gardasil Vaccine MDL
• UK Litigation Roundup: Here's What You Missed In London
• Male Sex Drug Labeled As 'Natural' Contains Viagra, Suit Says
• Calif. Jury Clears Bayer In Flea And Tick Med Antitrust Suit
• Latham, Ellenoff Rank Among Top Firms For July IPOs
• AliveCor Asks 9th Circ. To Revive Apple Watch Antitrust Case
• Chancery Denies Ex-InterMune CEO $6M Legal Fee Right
• JPML Won't Form MDL Of 35 Acne Product Benzene Suits
• Former Stimlabs Exec Doesn't Have To Hand Over Devices
• Novo Nordisk Loses Challenge To Medicare Drug Price Talks
• AbbVie Wants Mass. Biotech Firm To Pay Up For Drug Work
• MoFo Adds 3-Atty IP Litigation Team In NY From Desmarais
• Medtronic Still Faces Chancery Claim In Fortis' InPen Suit
• Expert Witness Standards Must Consider Peer Review Crisis
• R1 RCM Going Private In $8.9B Deal Steered By 4 Firms
• Analyzing Advance Notice Bylaws On 'Clear' Or 'Cloudy' Days
• DLA Piper Hires Longtime Williams & Jensen Partner In DC
• Biotech Co. Biedermann Motech Hits Ch. 11 With $34M Debt
• Hogan Lovells Recruits Two From Foley Hoag To Health Team